Youwen Zhuang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Youwen Zhuang has a total of 128 co-authors. Here are the top co-authors by number of shared publications:
- H. Eric Xu
CAS Key Laboratory of Receptor Research, Center for Structure and Function of Drug Targets, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
12 shared publications Qingning Yuan
Shanghai Institute of Materia Medica, Chinese Academy of Sciences
8 shared publications- Yue Wang
The State Key Laboratory of Drug Research, Center for Structure and Function of Drug Targets, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
8 shared publications Kai Wu
State Key Laboratory of Drug Research. Center for Structure and Function of Drug Targets, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
6 shared publications- Youwei Xu
The State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
6 shared publications Wenjia Fan
State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
5 shared publications
Latest Publications
- Open Access
Fine-tuning an intracellular allosteric pocket programs GPCR signaling bias
Biased signaling of G protein-coupled receptors (GPCRs) offers a route for precise therapeutics with fewer adverse effects. Intracellular allosteric ligands can impose such bias, yet how subtle chemical changes within these pockets reshape receptor-transducer coupling and downstream signaling remains unclear. Here, we systematically fine-tuned the intracellular allosteric pocket of neurotensin receptor 1 (NTSR1) through chemical modification of the β-arrestin-biased ligand SBI-553. Minor changes to the ligand scaffold altered transducer-coupling preferences, generating distinct profiles of G-protein and β-arrestin signaling. Cryo-electron microscopy structures of NTSR1-β-arrestin2 complexes bound to designed allosteric probes revealed ligand-dependent remodeling of the intracellular cavity that reshapes the receptor-effector interface. Alanine scanning identified transducer-sensitive residues within and beyond the immediate ligand-contact region. In mice, SBI-553 and N065 produced distinct physiological profiles, with N065 improving survival in a lethal endotoxemia model. Finally, phosphoproteomic profiling revealed partially overlapping but distinct downstream signaling profiles among the three modulators. Together, these findings establish the intracellular allosteric pocket as a tunable determinant of transducer coupling and show that closely related modulators can generate distinct signaling and physiological profiles.
Open AccessFine-tuning an intracellular allosteric pocket programs GPCR signaling bias
Biased signaling of G protein-coupled receptors (GPCRs) offers a route for precise therapeutics with fewer adverse effects. Intracellular allosteric ligands can impose such bias, yet how subtle chemical changes within these pockets reshape receptor-transducer coupling and downstream signaling remains unclear. Here, we systematically fine-tuned the intracellular allosteric pocket of neurotensin receptor 1 (NTSR1) through chemical modification of the β-arrestin-biased ligand SBI-553. Minor changes to the ligand scaffold altered transducer-coupling preferences, generating distinct profiles of G-protein and β-arrestin signaling. Cryo-electron microscopy structures of NTSR1-β-arrestin2 complexes bound to designed allosteric probes revealed ligand-dependent remodeling of the intracellular cavity that reshapes the receptor-effector interface. Alanine scanning identified transducer-sensitive residues within and beyond the immediate ligand-contact region. In mice, SBI-553 and N065 produced distinct physiological profiles, with N065 improving survival in a lethal endotoxemia model. Finally, phosphoproteomic profiling revealed partially overlapping but distinct downstream signaling profiles among the three modulators. Together, these findings establish the intracellular allosteric pocket as a tunable determinant of transducer coupling and show that closely related modulators can generate distinct signaling and physiological profiles.
- 23 October 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (43) , eaeh3401
Multiple allosteric sites allow for synergistic enhancement of GPCR signaling
Allosteric modulation of G protein–coupled receptors (GPCRs) offers promising therapeutic opportunities. Although multiple allosteric binding sites have been identified in GPCRs, whether and how these spatially distinct sites cooperate to regulate receptor activation remain poorly understood. Here, we elucidate the molecular mechanism of cooperative multisite allostery in the dopamine D1 receptor (D1R). We developed two novel D1R positive allosteric modulators (PAMs), UNC9815 and UNC10062, and used cryo–electron microscopy to structurally identify two previously uncharacterized D1R allosteric sites occupied by UNC9815/UNC10062 and another D1R PAM, BMS-A1. Both sites localize to the transmembrane helix (TM) 1 to 7 interface as vertically adjacent allosteric pockets organized in a spatially complementary manner. Our structures demonstrate the simultaneous binding of the chemically distinct PAMs (LY3154207, BMS-A1, and UNC9815/UNC10062) in three nonoverlapping pockets. Concurrent engagement of all three allosteric sites produces pronounced functional cooperativity, increasing dopamine potency by >1000-fold, thereby demonstrating that coordinated multisite modulation can achieve substantial pharmacological amplification beyond the limits imposed by single PAM administration. Molecular dynamics (MD) simulations revealed that multisite PAM engagement restricts intracellular loop 3 dynamics and stabilizes the TM7-NPxxY activation motif, effects not achieved by binding of LY3154207 alone, thereby biasing the receptor toward a more stabilized active conformation, and may also improve agonist potency by stabilizing extracellular loop 2. Together, these findings establish the structural framework for cooperative multisite allostery in a GPCR, revealing how distributed allosteric sites act in concert to amplify receptor activation and providing a conceptual foundation for developing innovative GPCR allosteric therapeutics.
- 23 October 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (43) , eaeh3401
Multiple allosteric sites allow for synergistic enhancement of GPCR signaling
Allosteric modulation of G protein–coupled receptors (GPCRs) offers promising therapeutic opportunities. Although multiple allosteric binding sites have been identified in GPCRs, whether and how these spatially distinct sites cooperate to regulate receptor activation remain poorly understood. Here, we elucidate the molecular mechanism of cooperative multisite allostery in the dopamine D1 receptor (D1R). We developed two novel D1R positive allosteric modulators (PAMs), UNC9815 and UNC10062, and used cryo–electron microscopy to structurally identify two previously uncharacterized D1R allosteric sites occupied by UNC9815/UNC10062 and another D1R PAM, BMS-A1. Both sites localize to the transmembrane helix (TM) 1 to 7 interface as vertically adjacent allosteric pockets organized in a spatially complementary manner. Our structures demonstrate the simultaneous binding of the chemically distinct PAMs (LY3154207, BMS-A1, and UNC9815/UNC10062) in three nonoverlapping pockets. Concurrent engagement of all three allosteric sites produces pronounced functional cooperativity, increasing dopamine potency by >1000-fold, thereby demonstrating that coordinated multisite modulation can achieve substantial pharmacological amplification beyond the limits imposed by single PAM administration. Molecular dynamics (MD) simulations revealed that multisite PAM engagement restricts intracellular loop 3 dynamics and stabilizes the TM7-NPxxY activation motif, effects not achieved by binding of LY3154207 alone, thereby biasing the receptor toward a more stabilized active conformation, and may also improve agonist potency by stabilizing extracellular loop 2. Together, these findings establish the structural framework for cooperative multisite allostery in a GPCR, revealing how distributed allosteric sites act in concert to amplify receptor activation and providing a conceptual foundation for developing innovative GPCR allosteric therapeutics.
- Open Access
Multi-vector retrieval enables residue-resolved prediction of protein partners by ColBERT-PPI
Protein–protein interactions (PPIs) are central to biological processes, making the identification of both interacting partners and their binding sites important for understanding molecular function and guiding therapeutic discovery. However, connecting large-scale partner prediction to residue-level interaction evidence remains challenging. Here we present ColBERT-PPI, a structure-aware multi-vector framework that links protein partner retrieval to interaction-site localisation. The model retains reusable residue-level representations and compares them in a partner-dependent manner, producing raw residue compatibility maps for localisation and calibrated smooth MaxSim scores for retrieval. On PINDER, ColBERT-PPI achieved an area under the precision–recall curve of 0.482, compared with 0.151 for the strongest evaluated external comparator. Both complete and sequence-only multi-vector models outperformed the single-vector control on an independent human yeast two-hybrid screen. Residue-level comparisons highlighted experimental interfaces, captured changes in local evidence across partners and achieved a mean contact AUROC of 0.806 versus 0.526 for the single-vector control. After task-specific fine-tuning, PPI-trained representations also improved protein-RNA interaction retrieval, indicating transfer beyond the molecular context in which they were learned. By connecting candidate partners with their supporting residue-level evidence, ColBERT-PPI provides a computational basis for investigating physiological and disease-associated interactions and prioritizing proteins and interaction regions for therapeutic exploration. Code is available at https://github.com/UR-Free/ColBERT-PPI .
Open AccessMulti-vector retrieval enables residue-resolved prediction of protein partners by ColBERT-PPI
Protein–protein interactions (PPIs) are central to biological processes, making the identification of both interacting partners and their binding sites important for understanding molecular function and guiding therapeutic discovery. However, connecting large-scale partner prediction to residue-level interaction evidence remains challenging. Here we present ColBERT-PPI, a structure-aware multi-vector framework that links protein partner retrieval to interaction-site localisation. The model retains reusable residue-level representations and compares them in a partner-dependent manner, producing raw residue compatibility maps for localisation and calibrated smooth MaxSim scores for retrieval. On PINDER, ColBERT-PPI achieved an area under the precision–recall curve of 0.482, compared with 0.151 for the strongest evaluated external comparator. Both complete and sequence-only multi-vector models outperformed the single-vector control on an independent human yeast two-hybrid screen. Residue-level comparisons highlighted experimental interfaces, captured changes in local evidence across partners and achieved a mean contact AUROC of 0.806 versus 0.526 for the single-vector control. After task-specific fine-tuning, PPI-trained representations also improved protein-RNA interaction retrieval, indicating transfer beyond the molecular context in which they were learned. By connecting candidate partners with their supporting residue-level evidence, ColBERT-PPI provides a computational basis for investigating physiological and disease-associated interactions and prioritizing proteins and interaction regions for therapeutic exploration. Code is available at https://github.com/UR-Free/ColBERT-PPI .
- Open Access
- 29 May 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Structural characterization of kappa-opioid receptor dimer in complex with two G proteins
The κ-opioid receptor (κOR) represents a promising non-addictive analgesic target due to its critical role in pain and reward pathways. Despite evidence of κOR dimerization, its molecular basis and pharmacological significance remain elusive. Here, we demonstrate stable κOR dimer formation in living cells and present cryo-electron microscopy structures of salvinorin A-bound κOR dimer complexed with two Gi proteins, revealing a parallel assembly distinct from previously characterized GPCR dimers that engage only single G protein. Multiple membrane lipids are positioned at the TM1-Helix 8 interface, where they make extensive contacts with both protomers and may contribute to the stability of the κOR dimer. Importantly, dimerization significantly enhances Gi protein recruitment to κOR in both potency and efficacy. We also demonstrate that salvinorin A, a non-nitrogenous agonist, binds similarly in monomeric and dimeric κOR, and identify Y3127.35 as a critical selectivity determinant across opioid receptors. These findings expand our understanding of opioid receptor pharmacology and signaling, providing a foundation for developing superior κOR-targeted therapeutics for pain and related disorders.
- 29 May 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessStructural characterization of kappa-opioid receptor dimer in complex with two G proteins
The κ-opioid receptor (κOR) represents a promising non-addictive analgesic target due to its critical role in pain and reward pathways. Despite evidence of κOR dimerization, its molecular basis and pharmacological significance remain elusive. Here, we demonstrate stable κOR dimer formation in living cells and present cryo-electron microscopy structures of salvinorin A-bound κOR dimer complexed with two Gi proteins, revealing a parallel assembly distinct from previously characterized GPCR dimers that engage only single G protein. Multiple membrane lipids are positioned at the TM1-Helix 8 interface, where they make extensive contacts with both protomers and may contribute to the stability of the κOR dimer. Importantly, dimerization significantly enhances Gi protein recruitment to κOR in both potency and efficacy. We also demonstrate that salvinorin A, a non-nitrogenous agonist, binds similarly in monomeric and dimeric κOR, and identify Y3127.35 as a critical selectivity determinant across opioid receptors. These findings expand our understanding of opioid receptor pharmacology and signaling, providing a foundation for developing superior κOR-targeted therapeutics for pain and related disorders.
- Open Access
- 14 April 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Rational design of a Kappa opioid receptor peptide agonist with attenuated β-arrestin signaling
Difelikefalin is an FDA-approved κ-opioid receptor (KOR) peptide agonist used to treat chronic pruritus. However, as a balanced agonist that activates both G protein and β-arrestin pathways, difelikefalin remains associated with undesirable side effects linked to β-arrestin signaling. Here, we report the cryo-EM structure of the difelikefalin-KOR-Gi complex, identifying Y320 7.43 as a key residue that is critical for signaling bias. Guided by this structural insight, we engineer beta01, a β-amino acid-substituted analog with potent G protein activation but minimal β-arrestin recruitment. In mouse models, beta01 retains robust antinociceptive and antipruritic efficacy while significantly reducing sedation and anxiety-like behaviors. Structural, molecular dynamics simulations and 2D 13 C-Met NMR analyses further reveal beta01 stabilizes a unique KOR conformation with an expanded intracellular cavity that disfavors β-arrestin binding. This work establishes a rational structure-based framework for designing safer and more effective GPCR-targeted therapeutics.
- 14 April 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessRational design of a Kappa opioid receptor peptide agonist with attenuated β-arrestin signaling
Difelikefalin is an FDA-approved κ-opioid receptor (KOR) peptide agonist used to treat chronic pruritus. However, as a balanced agonist that activates both G protein and β-arrestin pathways, difelikefalin remains associated with undesirable side effects linked to β-arrestin signaling. Here, we report the cryo-EM structure of the difelikefalin-KOR-Gi complex, identifying Y320 7.43 as a key residue that is critical for signaling bias. Guided by this structural insight, we engineer beta01, a β-amino acid-substituted analog with potent G protein activation but minimal β-arrestin recruitment. In mouse models, beta01 retains robust antinociceptive and antipruritic efficacy while significantly reducing sedation and anxiety-like behaviors. Structural, molecular dynamics simulations and 2D 13 C-Met NMR analyses further reveal beta01 stabilizes a unique KOR conformation with an expanded intracellular cavity that disfavors β-arrestin binding. This work establishes a rational structure-based framework for designing safer and more effective GPCR-targeted therapeutics.
- Top Cited PapersOpen Access
- 13 February 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (7) , eaea9832
Structure-based design of an opioid receptor modulator for enhanced morphine analgesia
The alarming rates of deaths due to opioid overdose present an urgent need for safer opioid analgesics. Positive allosteric modulators (PAMs) of opioid receptors (ORs) offer a promising approach to enhance opioid efficacy while reducing risks of overdose. In this study, we unveil the selective mechanism of PAM modulation of the OR family through structure elucidation of the δ-opioid receptor and μ-opioid receptor (μOR) bound to orthosteric agonists and PAMs BMS986187 (BMS187) and BMS986122 (BMS122). In addition, we uncovered an unexpected but conserved allosteric site across the transmembrane helices TM2 to TM4 of ORs, occupied by BMS187 but not BMS122. Leveraging these structural insights, we designed 9-(5-(4-chlorophenyl)furan-2-yl)-3,3,6,6-tetramethyl-3,4,5,6,7,9-hexahydro-1 H -xanthene-1,8(2 H )-dione (MPAM-15), whose αβ cooperativity factor is 33-fold higher than BMS122 and threefold higher than BMS187, indicating markedly stronger positive allosterism. Animal studies demonstrate that MPAM-15 shows excellent brain penetration and enhances morphine-induced antinociception without exacerbating respiratory depression or constipation. Molecular dynamics simulations revealed that MPAM-15 promotes and stabilizes the conformational equilibrium of μOR toward the canonical active state, providing a mechanistic basis for its enhanced allosteric potency. These discoveries substantially advance our understanding of OR allosteric mechanism and pave the way for the structure-based development of allosteric opioid analgesics.
- 13 February 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (7) , eaea9832
Top Cited PapersOpen AccessStructure-based design of an opioid receptor modulator for enhanced morphine analgesia
The alarming rates of deaths due to opioid overdose present an urgent need for safer opioid analgesics. Positive allosteric modulators (PAMs) of opioid receptors (ORs) offer a promising approach to enhance opioid efficacy while reducing risks of overdose. In this study, we unveil the selective mechanism of PAM modulation of the OR family through structure elucidation of the δ-opioid receptor and μ-opioid receptor (μOR) bound to orthosteric agonists and PAMs BMS986187 (BMS187) and BMS986122 (BMS122). In addition, we uncovered an unexpected but conserved allosteric site across the transmembrane helices TM2 to TM4 of ORs, occupied by BMS187 but not BMS122. Leveraging these structural insights, we designed 9-(5-(4-chlorophenyl)furan-2-yl)-3,3,6,6-tetramethyl-3,4,5,6,7,9-hexahydro-1 H -xanthene-1,8(2 H )-dione (MPAM-15), whose αβ cooperativity factor is 33-fold higher than BMS122 and threefold higher than BMS187, indicating markedly stronger positive allosterism. Animal studies demonstrate that MPAM-15 shows excellent brain penetration and enhances morphine-induced antinociception without exacerbating respiratory depression or constipation. Molecular dynamics simulations revealed that MPAM-15 promotes and stabilizes the conformational equilibrium of μOR toward the canonical active state, providing a mechanistic basis for its enhanced allosteric potency. These discoveries substantially advance our understanding of OR allosteric mechanism and pave the way for the structure-based development of allosteric opioid analgesics.
- Open Access
- 10 January 2025
- Published by Springer Nature in Cell Discovery
- Vol. 11 (1) , 1-4
Structural insights into the agonist activity of the nonpeptide modulator JR14a on C3aR
- 10 January 2025
- Published by Springer Nature in Cell Discovery
- Vol. 11 (1) , 1-4
Open AccessStructural insights into the agonist activity of the nonpeptide modulator JR14a on C3aR
- Open Access
- 3 October 2024
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 121 (41)
Selective ligand recognition and activation of somatostatin receptors SSTR1 and SSTR3
Somatostatin receptors (SSTRs) exert critical biological functions such as negatively regulating hormone release and cell proliferation, making them popular targets for developing therapeutics to treat endocrine disorders, especially neuroendocrine tumors. Although several panagonists mimicking the endogenous ligand somatostatin are available, the development of more effective and safer somatostatinergic therapies is limited due to a lack of molecular understanding of the ligand recognition and regulation of divergent SSTR subtypes. Here, we report four cryoelectron microscopy structures of G i -coupled SSTR1 and SSTR3 activated by distinct agonists, including the FDA-approved panagonist pasireotide as well as their selective small molecule agonists L-797591 and L-796778. Our structures reveal a conserved recognition pattern of pasireotide in SSTRs attributed to the binding with a conserved extended binding pocket, distinct from SST14, octreotide, and lanreotide. Together with mutagenesis analyses, our structures further reveal the dynamic feature of ligand binding pockets in SSTR1 and SSTR3 to accommodate divergent agonists, the key determinants of ligand selectivity lying across the orthosteric pocket of different SSTR subtypes, as well as the molecular mechanism underlying diversity and conservation of receptor activation. Our work provides a framework for rational design of subtype-selective SSTR ligands and may facilitate drug development efforts targeting SSTRs with improved therapeutic efficacy and reduced side effects.
- 3 October 2024
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 121 (41)
Open AccessSelective ligand recognition and activation of somatostatin receptors SSTR1 and SSTR3
Somatostatin receptors (SSTRs) exert critical biological functions such as negatively regulating hormone release and cell proliferation, making them popular targets for developing therapeutics to treat endocrine disorders, especially neuroendocrine tumors. Although several panagonists mimicking the endogenous ligand somatostatin are available, the development of more effective and safer somatostatinergic therapies is limited due to a lack of molecular understanding of the ligand recognition and regulation of divergent SSTR subtypes. Here, we report four cryoelectron microscopy structures of G i -coupled SSTR1 and SSTR3 activated by distinct agonists, including the FDA-approved panagonist pasireotide as well as their selective small molecule agonists L-797591 and L-796778. Our structures reveal a conserved recognition pattern of pasireotide in SSTRs attributed to the binding with a conserved extended binding pocket, distinct from SST14, octreotide, and lanreotide. Together with mutagenesis analyses, our structures further reveal the dynamic feature of ligand binding pockets in SSTR1 and SSTR3 to accommodate divergent agonists, the key determinants of ligand selectivity lying across the orthosteric pocket of different SSTR subtypes, as well as the molecular mechanism underlying diversity and conservation of receptor activation. Our work provides a framework for rational design of subtype-selective SSTR ligands and may facilitate drug development efforts targeting SSTRs with improved therapeutic efficacy and reduced side effects.
- Open Access
- 28 June 2024
- Published by Elsevier in Cell Reports
- Vol. 43 (7) , 114422
Molecular basis for the activation of PAF receptor by PAF
- 28 June 2024
- Published by Elsevier in Cell Reports
- Vol. 43 (7) , 114422
Open AccessMolecular basis for the activation of PAF receptor by PAF
- Top Cited Papers
- 11 May 2023
- Published by Springer Nature in Nature Chemical Biology
- Vol. 19 (11) , 1351-1360
Revealing the signaling of complement receptors C3aR and C5aR1 by anaphylatoxins
The complement receptors C3aR and C5aR1, whose signaling is selectively activated by anaphylatoxins C3a and C5a, are important regulators of both innate and adaptive immune responses. Dysregulations of C3aR and C5aR1 signaling lead to multiple inflammatory disorders, including sepsis, asthma and acute respiratory distress syndrome. The mechanism underlying endogenous anaphylatoxin recognition and activation of C3aR and C5aR1 remains elusive. Here we reported the structures of C3a-bound C3aR and C5a-bound C5aR1 as well as an apo-C3aR structure. These structures, combined with mutagenesis analysis, reveal a conserved recognition pattern of anaphylatoxins to the complement receptors that is different from chemokine receptors, unique pocket topologies of C3aR and C5aR1 that mediate ligand selectivity, and a common mechanism of receptor activation. These results provide crucial insights into the molecular understanding of C3aR and C5aR1 signaling and structural templates for rational drug design for treating inflammation disorders.
- 11 May 2023
- Published by Springer Nature in Nature Chemical Biology
- Vol. 19 (11) , 1351-1360
Top Cited PapersRevealing the signaling of complement receptors C3aR and C5aR1 by anaphylatoxins
The complement receptors C3aR and C5aR1, whose signaling is selectively activated by anaphylatoxins C3a and C5a, are important regulators of both innate and adaptive immune responses. Dysregulations of C3aR and C5aR1 signaling lead to multiple inflammatory disorders, including sepsis, asthma and acute respiratory distress syndrome. The mechanism underlying endogenous anaphylatoxin recognition and activation of C3aR and C5aR1 remains elusive. Here we reported the structures of C3a-bound C3aR and C5a-bound C5aR1 as well as an apo-C3aR structure. These structures, combined with mutagenesis analysis, reveal a conserved recognition pattern of anaphylatoxins to the complement receptors that is different from chemokine receptors, unique pocket topologies of C3aR and C5aR1 that mediate ligand selectivity, and a common mechanism of receptor activation. These results provide crucial insights into the molecular understanding of C3aR and C5aR1 signaling and structural templates for rational drug design for treating inflammation disorders.